Sygnature Discovery has been identified as one of London Stock Exchange Group’s 1000 Companies to Inspire Britain.
The report is a celebration of the UK’s fastest-growing and most dynamic small and medium sized businesses across the UK. To be included in the list, companies needed to show consistent revenue growth over a minimum of three years, significantly outperforming their industry peers. More detail on the methodology can be found in the report […]
2nd May 2017 – Nottingham, UK – Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has enhanced its Biophysics capability with the addition of GE Healthcare’s Biacore 8K SPR system to the Biacore T200 SPR system that the company already has in-house. As the newest member of GE Healthcare’s […]
21 April 2017 – Nottingham, UK – Sygnature Discovery has today been recognised with one of the UK’s most prestigious business awards – the Queen’s Award for Enterprise, International Trade. Today the company employs over 150 dedicated scientists who research potential new medicines to treat a host of debilitating and often fatal diseases. This […]
10th April 2017, Nottingham, UK – Dr Jonathan Williams, COO, has given the “Nottingham Post” a tour of the “Discovery Building”, Sygnature’s new “landmark” facility located in BioCity Nottingham. The company will begin the move into the new, state-of-the-art building later this month. Dr Williams told the “Nottingham Post”: “After Oxford, Cambridge and London, Nottingham […]
Sygnature Discovery ranked in FT1000: The Financial Times list of Europe’s 1,000 fastest-growing companies
7th April 2017 – Nottingham, UK – Sygnature Discovery has been ranked 906th in the Financial Times FT1000 . The FT1000 lists the 1,000 companies in Europe that have achieved the highest percentage growth in revenues between 2012 and 2015. As the Financial Times describes it, “Innovative and fast-growing companies are the driving force of the […]